Viking Therapeutics (VKTX) Expected to Announce Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is anticipated to release its earnings data before the market opens on Wednesday, April 23rd. Analysts expect Viking Therapeutics to post earnings of ($0.34) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05). During the same quarter last year, the firm earned ($0.25) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Trading Up 1.4 %

Shares of NASDAQ VKTX opened at $23.94 on Monday. The firm has a fifty day simple moving average of $26.94 and a two-hundred day simple moving average of $41.70. The firm has a market capitalization of $2.69 billion, a PE ratio of -23.94 and a beta of 0.84. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.86.

Analyst Upgrades and Downgrades

Several analysts have commented on VKTX shares. Citigroup began coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They issued a “neutral” rating and a $38.00 price objective for the company. Piper Sandler lowered their target price on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a report on Thursday, February 6th. The Goldman Sachs Group initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They set a “neutral” rating and a $30.00 price objective on the stock. Maxim Group decreased their price objective on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, B. Riley reissued a “buy” rating and issued a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

Insider Transactions at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan bought 1,240 shares of Viking Therapeutics stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average cost of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now owns 1,240 shares of the company’s stock, valued at $29,946. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.